论文部分内容阅读
目的 :探析Ⅲ期非小细胞肺癌运用新辅助化疗治疗的临床效果。方法 :选择2013年10月-2014年10月期间我院收治的Ⅲ期非小细胞肺癌患者68例为研究对象,随机将其分为两组,其中给予对照组手术治疗,而观察组术前给予新辅助化疗治疗,对两组的治疗效果进行比较。结果 :相比较对照组而言,观察组的手术切除率明显较高,组间比较差异显著(P<0.05);同时,两组在术后并发症发生率方面比较差异显著(P<0.05)。结论 :临床上运用新辅助化疗对Ⅲ期非小细胞肺癌患者进行治疗,不仅可以使手术切除率提高,还能减少并发症,促进患者恢复。
Objective: To explore the clinical effect of neoadjuvant chemotherapy in stage III non-small cell lung cancer. Methods: Sixty-eight patients with stage III NSCLC treated in our hospital from October 2013 to October 2014 were randomly selected and divided into two groups. Among them, the control group received surgical treatment, while the observation group received preoperative treatment. Neoadjuvant chemotherapy was given and the treatment effects of the two groups were compared. Results: Compared with the control group, the surgical resection rate was significantly higher in the observation group, and there was a significant difference between the two groups (P<0.05). At the same time, there was a significant difference in the incidence of postoperative complications between the two groups (P<0.05). . Conclusion : The clinical use of neoadjuvant chemotherapy for the treatment of stage III non-small cell lung cancer patients can not only improve the surgical resection rate, but also reduce complications and promote patient recovery.